Compliance Question of the Week – Laboratory

For 2024, which code is associated with assessing the balance of estrogen and progesterone in the vaginal squamous epithelium?

What considerations should healthcare providers keep in mind regarding the medical necessity criteria when deciding whether to separately bill or bundle codes 88740 and 88741 for transcutaneous procedures?

Which code should be used when enhancing cytology specimens to concentrate diagnostic material and remove background debris, using techniques like liquid-based slide preparation or monolayer method?

What are the specific procedural codes associated with leukapheresis or lymphocytapheresis?

How should urinalysis procedures not covered by codes 81000–81050 be reported according to the new CPT parenthetical guidance for 2024?

Which PLA code was added for bulk acoustic wave (BAW) biosensor immunoassay for SARS-CoV-2 (Coronavirus disease [COVID-19]) in the 2024 AMA CPT® Manual?

Why was code 87523 established and is it new for 2024?

Can we bill 80299 only once in 2024? Did the MUE change for code for this code?

For code 88141, does the reporting system used by the physician for the interpretation of pap smears impact the code selection?

How should a laboratory document the miles traveled to collect a specimen in 2024?

Can you explain some of the rationale behind new 2024 chemistry codes 86041-43, and 86366?

Did section 502 of the Further Continuing Appropriations and Other Extensions Act of 2024 create any changes regarding data reporting requirements for clinical diagnostic laboratory tests (CDLTs) and the phase-in of payment reductions under the CLFS?